News
Public · Published
Barclays maintains Exelixis at Equal-Weight, raises price target to $54 from $49
Barclays kept its Equal-Weight rating on Exelixis and raised its price target to $54 from $49, a 10.2% increase. The new target implies an 18.4% downside from the October 29 close of $66.20.
Published:
Updated:
What happened
Barclays kept its Equal-Weight rating on Exelixis and raised its price target to $54 from $49, a 10.2% increase. The new target implies an 18.4% downside from the October 29 close of $66.20.
Confirmed
Global impact / market context
A higher target still sits below the current share price, so Barclays sees the stock as roughly fully valued. The Equal-Weight rating means it expects the shares to perform in line with the broader market rather than outperform.
Analyst inference
Other recent analyst targets on Exelixis range from $51 to $65, so Barclays sits in the middle of that range. This spread suggests analysts disagree about how much more the share price can rise after its recent run.
Analyst inference
What to watch
- Barclays set a $54 price target that implies an 18.4% downside from the October 29 close of $66.20, so watch whether the shares move toward that target. Confirmed
- Watch whether other analysts change their ratings or price targets on Exelixis, since the three latest targets range from $51 to $65 and any shift could move the shares. Proposed
- Watch whether Exelixis reports results or guidance that justify the gap between its $66.20 share price and Barclays' lower target, which could change investor positioning. Analyst inference
Evidence
- Original source link unavailable